Combination of therapy with 5-fluorouracil and cisplatin with electroporation in human ovarian carcinoma model in vitro

Biomedicine and Pharmacotherapy

Volumn 68, Issue 5, 2014, Pages 573-580

  Saczko, Jolanta ^a   Kamińska, Iwona ^a   Kotulska, Malgorzata ^b   Bar, Julia ^a   Choromańska, Anna ^a   Rembiałkowska, Nina ^a   Biezuńska Kusiak, Katarzyna ^a   Rossowska, Joanna ^c   Nowakowska, Danuta ^a   Kulbacka, Julita ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b WROCLAW UNIVERSITY OF TECHNOLOGY   (Poland)

^c INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

Author keywords

5 fluorouracil; Cisplatin; Electrochemotherapy; Electropermeabilization; Human fibroblasts; Ovarian carcinoma

Indexed keywords

CISPLATIN; FLUOROURACIL; PROPIDIUM IODIDE; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; ELECTRIC FIELD; ELECTROCHEMICAL ANALYSIS; ELECTROCHEMOTHERAPY; ELECTROPORATION; FEMALE; FIBROBLAST; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; OVARIAN CANCER CELL LINE; OVARY CARCINOMA; PRIORITY JOURNAL; CELL DEATH; CELL SURVIVAL; DRUG DELIVERY SYSTEM; DRUG EFFECTS; FLOW CYTOMETRY; IC50; MIDDLE AGED; OVARIAN NEOPLASMS; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL DEATH; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DRUG DELIVERY SYSTEMS; ELECTROPORATION; FEMALE; FIBROBLASTS; FLOW CYTOMETRY; FLUOROURACIL; HUMANS; INHIBITORY CONCENTRATION 50; MIDDLE AGED; OVARIAN NEOPLASMS;

EID: 84905121322     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2014.05.005     Document Type: Article

References (29)

1. Kusakari T., Kariya M., Mandai M., Tsuruta Y., Hamid A.A., Fukuhara K., et al. C-erbB-2 or mutant Ha-ras induced malignant transformation of immortalized human ovarian surface epithelial cells in vitro. Br J Cancer 2003, 89:2293-2298.
2. Mir L.M., Gehl J., Sersa G., Collins C.G., Garbay J.R., Billard V., et al. Standard operating procedures of the electrochemotherapy: instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the CliniporatorTM by means of invasive or non-invasive electrodes. Eur J Cancer 2006, S4:14-25.
3. Ramirez L.H., Orlowski S., An D., Bindoula G., Dzodic R., Ardouin P., et al. Electrochemotherapy on liver tumours in rabbits. Br J Cancer 1998, 77:2104-2111.
4. Sersa G. The state-of-the-art of electrochemotherapy before the ESOPE study; advantages and clinical uses. Eur J Cancer 2006, S4:52-59.
5. Rols M.P. Electropermeabilization, a physical method for the delivery of therapeutic molecules into cells. Biochim Biophys Acta 2006, 1758(3):423-428.
6. Cemazar M., Jarm T., Sersa G. Cancer electrogene therapy with interleukin-12. Curr Gene Ther 2010, 10(4):300-311.
7. Miklavcic D., Mir L.M., Vernier T.P. Electroporation-based technologies and treatments. J Membr Biol 2010, 236(1):1-2.
8. Jaroszeski M.J., Coppola D., Nesmith G., Pottinger C., Hyacinthe M., Benson K., et al. Effects of electrochemotherapy with bleomycin on normal liver tissue in a rat model. Eur J Cancer 2001, 37(3):414-421.
9. Gehl J. Electroporation for drug and gene delivery in the clinic: doctors go electric. Methods Mol Biol 2008, 423:351-359.
10. Jarm T., Cemazar M., Miklavcic D., Sersa G. Antivascular effects of electrochemotherapy: implications in treatment of bleeding metastases. Expert Rev Anticancer Ther 2010, 10:729-746.
11. Malet-Martino M., Martino R. Clinical studies of three oral prodrugs of 5-fluorouracil (Capecitabine, UFTS-1): a review. Oncologist 2002, 7:288-323.
12. Vasey P., McMahon L., Paul J., Reed N., Kaye S.B. A phase II trial of capecitabine (Xeloda) in recurrent ovarian cancer. Br J Cancer 2003, 89(10):1843-1848.
13. Wawrocka-Pawlak M. How 5-fluorouracil acts (in Polish). Wsp Onkologia (Contemp Oncol) 2005, 9-10:414-423.
14. Florea A.M., Büsselberg D. Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers (Basel) 2011, 3(1):1351-1371.
15. Bar J.K., Harłozińska A., Kartarius S., Montenarh M., Wyrodek E., Rodriguez-Parkitna J.M., et al. Temperature-sensitive ovarian carcinoma cell line (OvBH-1). Jpn J Cancer Res 2002, 93(9):976-985.
16. Bar J.K., Harlozinska A. Morphological and phenotypic characterization of a new established ovarian carcinoma cell line (OvBH-1). Anticancer Res 2000, 20:2975-2980.
17. Saczko J., Dominiak M., Kulbacka J., Chwiłkowska A., Krawczykowska H. A simple and established method of tissue culture of human gingival fibroblasts for gingival augmentation. Folia Histochem Cytobiol 2008, 46:117-119.
18. Mir L.M., Belehradek M., Domenge C., Orlowski S., Poddevin B., Belehradek J., et al. Electrochemotherapy, a new antitumor treatment: first clinical trial. C R Acad Sci 1991, 313(13):613-618.
19. Kotulska M. Electrochemotherapy in cancer treatment. Adv Clin Exp Med 2007, 16(5):601-607.
20. Skołucka N., Saczko J., Kotulska M., Kulbacka J., Choromańska A. Electroporation and its application. Pol Merk Lek 2010, XXVIII(168):501.
21. Pucihar G., Kotnik T., Teissié J., Miklavcic D. Electropermeabilization of dense cell suspensions. Eur Biophys J 2007, 36:173-185.
22. Gehl J., Skovsgaard T., Mir L.M. Enhancement of cytotoxicity by electropermeabilization: an improved method for screening drugs. Anticancer Drugs 1998, 9(4):319-325.
23. Kulbacka J., Nowak M., Skołucka N., Saczko J., Kotulska M. The influence of electroporation on in vitro photodynamic therapy of human breast carcinoma cells. Folia Biol (Prague) 2011, 1(57):112-118.
24. Skolucka N., Daczewska M., Saczko J., Chwilkowska A., Choromanska A., Kotulska M., et al. ETM study of electroporation influence on cell morphology in human malignant melanoma and human primary gingival fibroblast cells. Asian Pac J Trop Biomed 2011, 1(2):94-98.
25. Bar J.K., Saczko J., Ziółkowski P., Chwiłkowska A., Słomska I., Drag Zalesińska M., et al. Photofrin II-based photosensitization of human ovarian clear-cell carcinoma cell line (OvBH-1). Pharmacol Rep 2007, 59:150-160.
26. Cemazar M., Sersa G., Miklavcic D. Electrochemotherapy with cisplatin in the treatment of tumor cells resistant to cisplatin. Anticancer Res 1998, 18(6A):4463-4466.
27. Sersa G., Cemazar M., Snoj M. Electrochemotherapy of tumours. Curr Oncol 2009, 16(2):34-35.
28. Yang X.J., Li J., Sun C.X., Zheng F.Y., Hu L.N. The effect of high frequency steep pulsed electric fields on in vitro and in vivo antitumor efficiency of ovarian cancer cell line skov3 and potential use in electrochemotherapy. J Exp Clin Cancer Res 2009, 28(53):1-9.
29. Edhemovic I., Gadzijev E.M., Brecelj E., Miklavcic D., Kos B., Zupanic A., et al. Electrochemotherapy: a new technological approach in treatment of metastases in the liver. Technol Cancer Res Treat 2011, 10(5):475-485.